"By fully adopting AI technology, smart pharmaceuticals can improve the quality of pharmaceutical enterprises in the whole chain from research and development, production, distribution to terminal consumption." This year, Zhang Boli, a NPC deputy and academician of the CAE Member, is still concerned about the development of China's pharmaceutical industry. In an interview with the reporter of Science and Technology Daily, he said that the pharmaceutical industry is a strategic industry related to the national economy and people's livelihood, economic development and national security, and is also an important foundation for the construction of a healthy China. China should adopt AI technology to transform the traditional pharmaceutical industry and enable the high-quality development of the pharmaceutical industry with smart pharmaceuticals. At present, China's economy has turned to the stage of high-quality development, which requires the pharmaceutical industry to speed up quality, efficiency and power changes. "Compared with automobile manufacturing, electronic manufacturing, metallurgy, petrochemical and other industries, the average level of automation in China's pharmaceutical industry is not high, and the concept and management level of information management are relatively low." Zhang Boli especially pointed out that "although most enterprises in the pharmaceutical industry have realized mechanized pharmacy, they have not yet established digital pharmaceutical production lines." Representatives of the National People's Congress, academicians of the CAE Member Xiao Wei, chairman of Jiangsu Kangyuan Pharmaceutical Co., Ltd., also felt deeply about this. He said that the pharmaceutical equipment in China's pharmaceutical industry is backward and the information integration is insufficient. "These conditions are reflected in capital, personnel, technological innovation ability and other aspects, which restrict the further improvement and improvement of drug production and management level and affect the continuous improvement of drug quality," Xiao Wei said. Through research, the scientific research team of Zhang Boli found that the comprehensive adoption of AI technology can not only improve the quality of the whole chain for pharmaceutical enterprises, but also help pharmaceutical enterprises enhance quality control, reduce quality risks, improve efficiency and optimize costs. At the same time, through the interconnection of production, quality control, logistics, marketing, human resources and other links, the intelligent manufacturing system can achieve the optimal scheduling of production materials and improve production efficiency. Take the traditional Chinese medicine industry as an example. At present, from the cultivation and production of medicinal materials, to the intellectualization of pharmaceutical equipment and diagnosis and treatment technology, to the transformation and landing of research evidence, the intellectualization of traditional Chinese medicine has a preliminary foundation. "Like the intelligent preparation production line of effective components of traditional Chinese medicine successfully developed by our team, the efficiency has been greatly improved," said Zhang Boli. Xiao Wei, as the head of a pharmaceutical enterprise, also understands the significance of smart pharmaceutical for the development of pharmaceutical enterprises. He said that the pharmaceutical industry can effectively improve the quality of drugs and optimize the production process only by establishing a quality control strategy and management system for data acquisition, analysis, optimization and traceability in the whole process with the help of digital and information technology. At the same time, it is also necessary to further integrate a variety of advanced technologies, promote the digital transformation of the whole factor and chain between enterprises and upstream and downstream, excavate data value, and realize data-driven decision-making and operation. "However, the weak foundation of information construction, rigid regulatory indicators and slow investment returns are the main problems faced by the pharmaceutical industry in the transformation of intelligent manufacturing." Zhang Boli suggested that the country should introduce policies to improve the level of pharmaceutical manufacturing technology and vigorously support the upgrading of the industry as a whole, "Relevant government departments can actively promote the transformation and improvement of green intelligent manufacturing technology in pharmaceutical process under the premise of ensuring the quality of drugs through innovation and optimization of drug review policies